TORONTO, ON -- (Marketwired) -- 08/06/14 -- Easton Pharmaceuticals Inc. (OTC: EAPH) announces it has in keeping with its prior outlined timeline; made a site visit of the mPact -GROzone Antimicrobial System prior to shipping to one of the largest medical marijuana growers in the United States.
As previously announced, Easton Pharmaceuticals has paid and acquired an initial ownership interest in AMFIL Technologies and its mPact -GROzone Antimicrobial System, with an option to purchase a much bigger 32.5% or more ownership interest in the company. Late last week, AMFIL's lead scientist and inventor provided an introductory viewing and presentation of a finished mPact -GROzone unit prior to being integrated into a commercially licensed, state of the art medical marijuana grow facility in Colorado. The mPact -GROzone Antimicrobial Systems is an exclusive application geared initially towards the Medical Marijuana Industry and marijuana growing/processing facilities as well as other pharmaceutical and food related applications. The mPact -GROzone Antimicrobial System is derived from the existing mPact technology which was mainly focused towards the food and beverage industries with successfully installed and performing units in the Food/Beverage and Fresh Produce Industries, e.g. Sysco Foods, Nestles, Sun Pacific, Thornbury Apple Cidery, Golden Town Apple, etc. Foodservices unit's website is http://www.acts-systems.com/ Current concerns regarding consumable recalls has fueled a growing niche market which has now been created within the burgeoning Medical Marijuana industry in both the United States, Canada as well as other parts of the world.
A picture of the system is to be uploaded to our website for viewing within the next few days. The company will be provided with additional pictures and video of a finished unit this week which will be able to be viewed on the company's website in the coming days.
Amfil Technologies Inc. has informed Easton of its plans to ship and install the unit within (approximately) the next two weeks and will supply Easton with photos of the installation and feedback on its operation from the master grower and facility owners. Amfil Technologies Inc. is in early stage discussions with various other well-known companies, both public and private in the United States and Canada and anticipates extremely positive and exciting news on other Grozone unit integration(s) within the near term to one or more large well known companies.
The mPact -GROzone Antimicrobial Systems product line eliminates the problems encountered in medicinal marijuana and all types of grow facilities in general by providing a sanitization unit that is a combination of two ozone technologies. It is multi-functional system which eliminates 99.9% of airborne pathogens, mold and pests such as aphids, whiteflies and spider mites that develop in medical marijuana grow facilities. It is also allows for constant and regulated PPM's of ozone to filter and purify the reservoir and liquid solutions used in growing mediums to prevent algae, bacterial culture and mold growth. The system, in general will also provide multi-surface cleaning to equipment, walls and floors, airborne pathogens and pests; as well as producing biologically stable water that does not promote excessive bacterial growth and regrowth in the distribution system feeding the growing medium. This oxygen based 'green' technology is an excellent environmentally friendly alternative and replacement to the harmful and carcinogenic chemicals currently being used in the industry and by oxygenating the water and delivering the regulated PPM doses in the water supply, the overall health, well-being and yield of the plant should be noticeable compared to similar plants not utilizing the system. It is expected that as an added by-product of installing the mPact -GROzone Antimicrobial Systems, room temperature will also be kept slightly cooler alleviating stress off the fans, hepa filters and ventilation systems, increased odor control, there will be reduced C02 usage and water consumption will be lowered.
In other developments, Easton Pharmaceuticals has recently been provided with a detailed update and viewed correspondence between Health Canada and the private medical marijuana grower the company maintains an exclusive option to purchase up to a 50% ownership interest in. The company whose name cannot be disclosed until a final inspection has been completed, is one of only 43 growers who have received a letter to build prior to receiving its license under the new MMPR mandate. Correspondence has been extremely promising and positive. Easton anticipates providing a positive and significant update sometime in the near term towards its interest in the National growers license for the country of Canada.
In other news, Eastons management and its corporate attorneys have notified web based investor portal Investorhub of its intent to serve them with a lawsuit and possible class action lawsuit after an investigation has determined that the vast majority of long term Easton investors have been either removed or have had their posts removed as part of what Easton and other company's believes is proof of abuse of moderator discretion, and biased censorship by investorhub. Although Investorhub has been known to be an investor chat board for mis-information and is not considered a serious site for any credible investor information, it is still viewed by some who are not aware of these facts. Following the investigation, Eastons management has made the decision to take action and attempt to stop the spreading of clear deception by bashers who are known to not have ever been investors of the company's stock. The company believes in free speech and to one's own personal opinions, but similar to articles written by individuals who have not attempted to contact the company and who have also spread deceitful mis-information for their own paid special interests, Easton and other companies cannot and will not sit while long term investors have their positive views or posts removed while others have made over 81,000 negative bashing posts on raging bull and now investorhub. These same posters have been previously sued by other companies and is now known to be as fact that these individuals have been paid to post negative defamatory comments with no actions being taken by Investorhub unlike Raging bull. Easton management requests that any valid information or answers to any questions being sought by investors be forwarded directly to the company through its website or by email at email@example.com
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors that owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues related towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company is also endeavoring to enter other potentially lucrative industries such as medical marijuana. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals' product "VIORRA" is an over-the-counter, topical daily use product and aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder).
For More Information Visit:
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.